Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Pancreatic Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1Advanced Malignancies 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × MLN8054 × Clear all
NCT00652158 2013-09-23

A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignancies

Millennium Pharmaceuticals, Inc.

Phase 1 Terminated
44 enrolled

Advanced Malignancies

NCT00249301 2008-04-01

A Study of MLN8054 in Patients With Advanced Solid Tumors

Millennium Pharmaceuticals, Inc.

Phase 1 Terminated
63 enrolled
BreastGastrointestinalGenitourinary

Urinary Bladder Neoplasms, Breast Neoplasms, Colonic Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡